ATYR1923-C-004: A Phase 3, Randomized, Double-Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Intravenous Efzofitimod in Patients with Pulmonary Sarcoidosis

Efzofitimod is being tested for the treatment of pulmonary sarcoidosis. This study is being done to learn more about this drug, specifically to see if taking efzofitimod will allow people to reduce the dose of steroids they are taking to treat their disease and find out more about the effects of different doses of efzofitimod on the lungs of people who have pulmonary sarcoidosis. This study will also look at how the body responds to the drug. These things will be measured by taking samples of blood, recording steroid dose, medical examinations performed by the study doctor, lung function tests, and responses to the questionnaires that will be completed throughout the study. Subjects in this study will receive monthly doses of the study drug or placebo for a total of 12 doses.

Scholars @ ECU